The objectives of this research were to prepare and characterize inclusion complexes of Artemether and Lumefantrine with hydroxypropyl-ß-cyclodextrin (HP-?-CD) and to study the effect of complexation on the dissolution rate of Artemether and Lumefantrine, water-insoluble drugs. The stoichiometric ratio determined by phase solubility analysis for inclusion complexes of Artemether and Lumefantrine with HP-?-CD was 1:1.5. Binary complexes were prepared by different methods such as kneading and physical mixing method and were further characterized using DSC and FT-IR. These studies indicated that a complex prepared by kneading method had successful inclusion of the Artemether and Lumefantrine molecule into the cyclodextrin cavity. The mean dissolution time for Artemether and Lumefantrine decreased significantly after preparing complexes using kneading method compare to its physical mixture and plain form. The similarity factor indicated a significant difference between the release profiles of Artemether and Lumefantrine from complexes and to its physical mixture and plain form. Hard gelatin capsules containing single dose of Artemether and Lumefantrine (20-120mg) with cyclodextrins had significant improvement in the release profile of both drugs as compared to market formulation containing multiple dose (80-480 mg tablet) of Artemether and Lumefantrine without cyclodextrin.
Cite this article:
Sanjesh Rathi, Dhaval Patel, Shrenik Shah. Physicochemical Characterization and In-Vitro Dissolution Behavior of Artemether and Lumefantrine: Hydroxypropyl-Β-Cyclodextrin Inclusion Complex. Research J. Pharm. and Tech 2020; 13(3): 1137-1141. doi: 10.5958/0974-360X.2020.00209.7
1. Janssens S, Van D, “Review: physical chemistry of solid
dispersions.” J Pharm Pharmacol, 2009, 61 (12), 1571-1586.
2. Leuner C, Dressman J, “Improving drug solubility for
oral delivery using solid dispersions.” Eur J Pharm Biopharm, 2000, 50(1),
3. Arunachalam M, Karthikeyan M, “Solid dispersions: A
review.” Current Pharm Res, 2010, 1(1), 82-90.
4. Mooter G, “The use of amorphous solid dispersions: A
formulation strategy to overcome poor solubility and dissolution rate.” Drug
Discov Today, 2012, 9 (2), 9-85.
5. Kapoor B, Kaur R, Kaur S, “Solid Dispersion: An Evolutionary
Approach for Solubility Enhancement of Poorly Water Soluble Drugs.” Int J
Rec Adv Pharm Res, 2012, 2(2), 1-16.
6. Lim S, Pang Z, Tan H, Shaikh M, Adinarayana G.
“Enhancement of docetaxel solubility using binary and ternary solid dispersion
systems.” Drug Dev Ind Pharm, 2015, 41(11), 1847-1855.
7. Jain C, Sharma A. “Solid dispersion: A promising
technique to enhance solubility of poorly water soluble drug.” Int J of Drug
Delivery, 2011, 3, 149-170.
8. Baghel R.S., Singh S., Yadav L. “A review on solid
dispersion.” Int J of Pharm & Life Sci.2011, 2, 1078-1095.
9. Huda N, Saffoon N, Sutradhar K, Uddin R. “Enhancement
of Oral Bioavailability and Solid Dispersion: A Review.” Journal of Applied
Pharm Sci, 2011, 1, 13-20.
10. Arunachalam A., Ashutoshkumar S., Karthikeyan M.,
Konam K., Prasad P.H., Sethuraman S. “Solid Dispersions: A Review.” Current
Pharm Research, 2010, 1, 82-90.
11. Singh S., Baghel R., Yadav L. “Review on Solid
Dispersion.” Int. Journal of Pharmacy and Life Sciences, 2011, 2 (9),